Drug intelligence / Profile preview

jianpi yishen huazhuo granules

Development stage: Unknown
Lead developer: Guizhou Bailing Group Pharmaceutical
Administration: Oral

Overview

Jianpi Yishen Huazhuo granules is a Traditional Chinese Medicine (TCM) formulation developed by Xiyuan Hospital of the China Academy of Traditional Chinese Medicine for the treatment of vascular dementia. The formulation is designed to address the TCM syndromes of spleen–kidney deficiency and phlegm–blood stasis, which are hypothesized to contribute to the pathogenesis of cognitive impairment following cerebrovascular events. By tonifying the spleen and kidney and promoting the resolution of phlegm and blood stasis, the granules aim to improve cognitive performance and daily functioning. It is currently undergoing Phase 2 clinical evaluation in China to establish its safety and therapeutic efficacy.

Other names: Jianpi Yishen Huazhuo granules

Beyond the preview

Go deeper on jianpi yishen huazhuo granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jianpi yishen huazhuo granules.

Explore the full profile